Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies

Authors: Kapetanovic et al. DOI: 10.1038/s41551-024-01255-xCentral Idea: This study demonstrates a method to engineer allogeneic T cells that are unresponsive to their native target antigen, thereby reducing the risk of graft-versus-host disease (GvHD), while retaining their ability to be activated by bispecific antibodies (biAbs) for cancer immunotherapy. These "Allogeneic-Engineered-Decoupled" (AED) T cells could pave the way for "off-the-shelf" T cell therapies combined with biAbs.Key Concepts:BiAb limitations: Current biAb therapies rely on the patient's own T cells, which are often compromised in cancer patients, limiting effectiveness. Allogeneic T cells offer a potential solution, but risk causing GvHD.Decoupling TCR and CD3 signaling: Researchers engineered T cells by mutating a conserved motif (FGxGT) within the T cell receptor (TCR) alpha chain. This mutation disrupts the link between TCR antigen recognition and downstream CD3 signaling activation.AED T cell function: AED T cells don't respond to their native antigen but can still be activated through CD3 by biAbs like blinatumomab, triggering their cancer-killing abilities.In vitro validation: AED T cells showed reduced proliferation, cytokine release, and cytotoxicity in response to their native antigen, but normal activation and tumor cell killing when stimulated with blinatumomab and CD19+ tumor cells.In vivo validation (mouse model): AED T cells effectively eliminated CD19+ tumors in mice when combined with blinatumomab, without signs of alloreactivity. Control allogeneic T cells did show signs of alloreactivity.Further Research/Unanswered Questions:Optimizing the engineering process and exploring other mutations for even more precise control of T cell activity.Testing the effectiveness of AED T cells with different types of biAbs and against various cancer types.Addressing the potential for host-versus-graft disease (HvGD), where the recipient's immune system attacks the donor T cells.Investigating the long-term safety and efficacy of AED T cell therapy in human clinical trials.